BR0312666A - Combinação de um inibidor alcina alostérico de metaloproteinase-13 de matriz com um inibidor seletivo da cicloxigenase-2 à exceção de celecoxib e do valdecoxib - Google Patents

Combinação de um inibidor alcina alostérico de metaloproteinase-13 de matriz com um inibidor seletivo da cicloxigenase-2 à exceção de celecoxib e do valdecoxib

Info

Publication number
BR0312666A
BR0312666A BR0312666-8A BR0312666A BR0312666A BR 0312666 A BR0312666 A BR 0312666A BR 0312666 A BR0312666 A BR 0312666A BR 0312666 A BR0312666 A BR 0312666A
Authority
BR
Brazil
Prior art keywords
inhibitor
pharmaceutically acceptable
acceptable salt
allosteric
combination
Prior art date
Application number
BR0312666-8A
Other languages
English (en)
Portuguese (pt)
Inventor
William Howard Roark
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0312666A publication Critical patent/BR0312666A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0312666-8A 2002-07-17 2003-07-07 Combinação de um inibidor alcina alostérico de metaloproteinase-13 de matriz com um inibidor seletivo da cicloxigenase-2 à exceção de celecoxib e do valdecoxib BR0312666A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39638502P 2002-07-17 2002-07-17
PCT/IB2003/003043 WO2004007025A1 (fr) 2002-07-17 2003-07-07 Combinaison d'un inhibiteur alcyne allosterique de metalloproteinase matricielle 13 avec un inhibiteur selectif de cyclooxygenase-2, a l'exception du celecoxib ou du valdecoxib

Publications (1)

Publication Number Publication Date
BR0312666A true BR0312666A (pt) 2005-05-10

Family

ID=30116021

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312666-8A BR0312666A (pt) 2002-07-17 2003-07-07 Combinação de um inibidor alcina alostérico de metaloproteinase-13 de matriz com um inibidor seletivo da cicloxigenase-2 à exceção de celecoxib e do valdecoxib

Country Status (8)

Country Link
US (1) US20040019055A1 (fr)
EP (1) EP1525030A1 (fr)
JP (1) JP2006502991A (fr)
AU (1) AU2003281168A1 (fr)
BR (1) BR0312666A (fr)
CA (1) CA2491820A1 (fr)
MX (1) MXPA05000638A (fr)
WO (1) WO2004007025A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
US7465795B2 (en) 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
CN104592128A (zh) 2005-12-20 2015-05-06 阿斯利康(瑞典)有限公司 作为gabaa受体调节剂的取代的噌啉衍生物及其合成方法
US9763984B2 (en) 2012-12-21 2017-09-19 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US161000A (en) * 1875-03-23 Improvement in millstone-bushes
US156061A (en) * 1874-10-20 Improvement in boot and shoe nails
US144274A (en) * 1873-11-04 Improvement in self-closing telegraph-keys
US151555A (en) * 1874-06-02 Improvement in street-railway switches
US130278A (en) * 1872-08-06 Improvement in pipe-tongs
US78276A (en) * 1868-05-26 George m
US151558A (en) * 1874-06-02 Improvement in the modes of machine-sewing
US156069A (en) * 1874-10-20 Improvement in lithographic printing-presses
DE3171475D1 (en) * 1980-05-31 1985-08-29 Ciba Geigy Ag Aryl-phenyl-acetylene compounds
US4902796A (en) * 1986-10-20 1990-02-20 The Trustees Of Princeton University 6-alkenyl and ethynyl derivatives of 2-amino-4-hydroxypyrido[2,3-d]pyrimidines
US4818819A (en) * 1986-10-20 1989-04-04 The Trustees Of Princeton University Process for the preparation of fused pyridine compounds
BR9607240A (pt) * 1995-03-14 1997-11-11 Norvatis Ag Derivados de fenila trissubstituidos
US5644141A (en) * 1995-10-12 1997-07-01 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Apparatus and method for high-speed characterization of surfaces
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
BR9714385A (pt) * 1996-12-09 2000-05-16 Warner Lambert Co Método para tratamento e prevenção de deficiência cardìaca e dilatação ventricular
UA59453C2 (uk) * 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
US6225311B1 (en) * 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
PA8556301A1 (es) * 2001-10-12 2003-09-05 Warner Lambert Co Compuestos pirimidina de anillo fusionado alquinilado
EP1434585A1 (fr) * 2001-10-12 2004-07-07 Warner-Lambert Company LLC Inhibiteurs de metalloproteinase matricielle (mmp) a base d'alkyne

Also Published As

Publication number Publication date
US20040019055A1 (en) 2004-01-29
JP2006502991A (ja) 2006-01-26
AU2003281168A1 (en) 2004-02-02
CA2491820A1 (fr) 2004-01-22
WO2004007025A1 (fr) 2004-01-22
EP1525030A1 (fr) 2005-04-27
MXPA05000638A (es) 2005-03-31

Similar Documents

Publication Publication Date Title
US6362190B2 (en) Method for treating inflammatory diseases by administering a thrombin inhibitor
BR0312736A (pt) Associação de um inibidor carboxìlico alostérico da metaloproteinase-13 de matriz com celecoxib ou valdecoxib
UY27533A1 (es) Composiciones farmacéuticas que contienen oxibutinina
AR033855A1 (es) Composiciones y combinaciones de activador(es) del receptor de activacion de proliferacion peroxis0mal (ppar) e inhibidor(es) de absorcion de esterol, el uso de dichas composiciones o combinaciones para la manufactura de un medicamento para el tratamiento para indicaciones vasculares, diabetes, obes
BR9809968A (pt) Aplicação de derivados tiazolidinadiona no tratamento da pcos e diabetes gestacional
BR0005276A (pt) Compostos para o tratamento de disfução sexual feminina
BR0209468A (pt) Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar
BRPI0407618A (pt) derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização
CA2217455A1 (fr) Nouveaux derives substitues, de biphenyle ou de phenylpiridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
NO952309D0 (no) Anvendelse av riluzol ved behandling av Parkinsons sykdom og Parkinsonske syndromer
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
AR011231A1 (es) Uso de un mejorador de sensibilidad a la insulina y composicion farmaceutica que comprende dicho mejorador
BR0313148A (pt) Formulações de liberação controlada compreendendo lamotrigina
Armour et al. Inhibition of bone resorption in vitro and prevention of ovariectomy‐induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026)
BR0014946A (pt) Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina
BR0312727A (pt) Combinação de um inibidor alostérico da metaloproteinase-13 de matriz com celecoxib ou valdecoxib
BR0312744A (pt) Associação de um inibidor carboxìlico alostérico da metaloproteinase-13 de matriz com um inibidor selectivo da ciclooxigenase-2, à excepção do celecoxib ou valdecoxib
BR0312943A (pt) Combinação de um inibidor alostérico de matriz metaloproteinase-13 com um inibidor seletivo de ciclooxigenase-2 que não é celecoxib ou valdecoxib
CO5570661A2 (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
BR0312666A (pt) Combinação de um inibidor alcina alostérico de metaloproteinase-13 de matriz com um inibidor seletivo da cicloxigenase-2 à exceção de celecoxib e do valdecoxib
BR0312708A (pt) Combinação de um inibidor alcina alostérico de metaloproteinase-13 de matriz com celecoxib ou valdecoxib
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
BR0212583A (pt) Agonistas i para retinóides de alquil uréia
KR970706811A (ko) I형 알레르기성 질환의 예방 및 치료제(Preventive and remedy for type Ⅰ allergic diseases)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 5A,, 6A. E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/415 (2006.01), A61P 19/02 (2006.01), A61P